(Bloomberg) -- A $10 version of Sovaldi, the Gilead
Sciences Inc. hepatitis C treatment that sells for $1,000 a pill
in the U.S., is now available in Bangladesh and could make its
way to other parts of the world where the U.S. company doesn’t
have patents.
Incepta Pharmaceuticals Ltd. doesn’t have a license from
Gilead and its version was launched last month, said Managing
Director Abdul Muktadir. The company also aims to sell the drug
overseas, including to parts of Southeast Asia and Africa.
The generic drugmaker has beaten to the market a number of
larger Indian competitors that were licensed by Gilead to
produce low-cost versions of Sovaldi for 91 countries that are
mostly poor. Nations not covered by Gilead’s license, including
Thailand, Malaysia and Morocco, and countries where Sovaldi
isn’t patented could benefit from the new source of cheap
copies.
Read more... Labels: Bangladesh, cost of drugs, generic Sovaldi, Incepta